Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Chemistry of verongida sponges. 9.1 secondary metabolite composition of the caribbean sponge aplysina cauliformis .

Journal of natural products

Ciminiello P, Dell'Aversano C, Fattorusso E, Magno S, Pansini M.
PMID: 10217716
J Nat Prod. 1999 Apr;62(4):590-3. doi: 10.1021/np9805138.

A detailed analysis of the secondary metabolites of the sponge Aplysina cauliformis has been performed. Eight compounds were identified, two of which (13 and 14) are new bromotyrosine derivatives whose structures were determinated from spectroscopic evidence, including 2D NMR....

Cite
Ciminiello P, Dell'Aversano C, Fattorusso E, et al. Chemistry of verongida sponges. 9.1 secondary metabolite composition of the caribbean sponge aplysina cauliformis . J Nat Prod. 1999;62(4):590-3doi: 10.1021/np9805138.
Ciminiello, P., Dell'Aversano, C., Fattorusso, E., Magno, S., & Pansini, M. (1999). Chemistry of verongida sponges. 9.1 secondary metabolite composition of the caribbean sponge aplysina cauliformis . Journal of natural products, 62(4), 590-3. https://doi.org/10.1021/np9805138
Ciminiello, et al. "Chemistry of verongida sponges. 9.1 secondary metabolite composition of the caribbean sponge aplysina cauliformis ." Journal of natural products vol. 62,4 (1999): 590-3. doi: https://doi.org/10.1021/np9805138
Ciminiello P, Dell'Aversano C, Fattorusso E, Magno S, Pansini M. Chemistry of verongida sponges. 9.1 secondary metabolite composition of the caribbean sponge aplysina cauliformis . J Nat Prod. 1999 Apr;62(4):590-3. doi: 10.1021/np9805138. PMID: 10217716.
Copy Download .nbib Format: NLM
ESVM integrated care pathways - a call for action.

VASA. Zeitschrift fur Gefasskrankheiten

Visonà A, Pesavento R, Mazzolai L, Cimminiello C, Pécsvárady Z, Olinic D, Johansson E.
PMID: 30821213
Vasa. 2019 Mar;48(2):113-114. doi: 10.1024/0301-1526/a000755.

No abstract available.

Cite
Visonà A, Pesavento R, Mazzolai L, et al. ESVM integrated care pathways - a call for action. Vasa. 2019;48(2):113-114doi: 10.1024/0301-1526/a000755.
Visonà, A., Pesavento, R., Mazzolai, L., Cimminiello, C., Pécsvárady, Z., Olinic, D., & Johansson, E. (2019). ESVM integrated care pathways - a call for action. VASA. Zeitschrift fur Gefasskrankheiten, 48(2), 113-114. https://doi.org/10.1024/0301-1526/a000755
Visonà, Adriana, et al. "ESVM integrated care pathways - a call for action." VASA. Zeitschrift fur Gefasskrankheiten vol. 48,2 (2019): 113-114. doi: https://doi.org/10.1024/0301-1526/a000755
Visonà A, Pesavento R, Mazzolai L, Cimminiello C, Pécsvárady Z, Olinic D, Johansson E. ESVM integrated care pathways - a call for action. Vasa. 2019 Mar;48(2):113-114. doi: 10.1024/0301-1526/a000755. PMID: 30821213.
Copy Download .nbib Format: NLM
Current status and perspectives in immunotherapy for metastatic melanoma.

Oncotarget

Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P.
PMID: 29552325
Oncotarget. 2018 Jan 03;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23.

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking...

Cite
Marconcini R, Spagnolo F, Stucci LS, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9(15):12452-12470doi: 10.18632/oncotarget.23746.
Marconcini, R., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F., Picasso, V., Di Guardo, L., Cimminiello, C., Cavalieri, S., Orgiano, L., Tanda, E., Spano, L., Falcone, A., Queirolo, P. (2018). Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget, 9(15), 12452-12470. https://doi.org/10.18632/oncotarget.23746
Marconcini, Riccardo, et al. "Current status and perspectives in immunotherapy for metastatic melanoma." Oncotarget vol. 9,15 (2018): 12452-12470. doi: https://doi.org/10.18632/oncotarget.23746
Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, Cavalieri S, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018 Jan 03;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. PMID: 29552325; PMCID: PMC5844761.
Copy Download .nbib Format: NLM
Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey.

BJGP open

Cimminiello C, Hatala R, Pakarinen S, Polo Friz H, Fitzmaurice D, Hobbs FR.
PMID: 30564735
BJGP Open. 2018 Aug 22;2(3):bjgpopen18X101602. doi: 10.3399/bjgpopen18X101602. eCollection 2018 Oct.

BACKGROUND: Familiarity and competency in the options for stroke prevention in atrial fibrillation (AF) and the role of non-vitamin K antagonist oral anticoagulants (NOACs) may vary among primary care physicians (PCPs) from different European countries.AIMS: To investigate PCP views...

Cite
Cimminiello C, Hatala R, Pakarinen S, et al. Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open. 2018;2(3):bjgpopen18X101602doi: 10.3399/bjgpopen18X101602.
Cimminiello, C., Hatala, R., Pakarinen, S., Polo Friz, H., Fitzmaurice, D., & Hobbs, F. R. (2018). Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP open, 2(3), bjgpopen18X101602. https://doi.org/10.3399/bjgpopen18X101602
Cimminiello, Claudio, et al. "Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey." BJGP open vol. 2,3 (2018): bjgpopen18X101602. doi: https://doi.org/10.3399/bjgpopen18X101602
Cimminiello C, Hatala R, Pakarinen S, Polo Friz H, Fitzmaurice D, Hobbs FR. Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey. BJGP Open. 2018 Aug 22;2(3):bjgpopen18X101602. doi: 10.3399/bjgpopen18X101602. eCollection 2018 Oct. PMID: 30564735; PMCID: PMC6189775.
Copy Download .nbib Format: NLM
Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.

Current vascular pharmacology

De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C.
PMID: 32819249
Curr Vasc Pharmacol. 2021;19(5):542-555. doi: 10.2174/1570161118666200820141131.

BACKGROUND: Clopidogrel monotherapy is guideline-recommended in symptomatic peripheral artery disease (PAD). The advent of new antithrombotic strategies prompts an updated analysis of available evidence on antiplatelet therapy for PAD.METHODS: We searched MEDLINE, Embase and CENTRAL through January 2019 for...

Cite
De Carlo M, Di Minno G, Sayre T, et al. Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Curr Vasc Pharmacol. 2021;19(5):542-555doi: 10.2174/1570161118666200820141131.
De Carlo, M., Di Minno, G., Sayre, T., Fazeli, M. S., Siliman, G., & Cimminiello, C. (2021). Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Current vascular pharmacology, 19(5), 542-555. https://doi.org/10.2174/1570161118666200820141131
De Carlo, Marco, et al. "Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis." Current vascular pharmacology vol. 19,5 (2021): 542-555. doi: https://doi.org/10.2174/1570161118666200820141131
De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C. Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Curr Vasc Pharmacol. 2021;19(5):542-555. doi: 10.2174/1570161118666200820141131. PMID: 32819249; PMCID: PMC8573731.
Copy Download .nbib Format: NLM
Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Diamanti L, Picca A, Bini P, Gastaldi M, Alfonsi E, Pichiecchio A, Rota E, Rudà R, Bruno F, Villani V, Galiè E, Vogrig A, Valente M, Zoccarato M, Poretto V, Giometto B, Cimminiello C, Del Vecchio M, Marchioni E.
PMID: 34424427
Neurol Sci. 2021 Aug 23; doi: 10.1007/s10072-021-05561-z. Epub 2021 Aug 23.

BACKGROUND: Neurological immune-related adverse events (nirAEs) are rare toxicities of immune-checkpoint inhibitors (ICI). With the increase of ICI oncological indications, their incidence is growing. Their recognition and management remain nevertheless challenging.METHODS: A national, web-based database was built to collect...

Cite
Diamanti L, Picca A, Bini P, et al. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci. 2021;doi: 10.1007/s10072-021-05561-z.
Diamanti, L., Picca, A., Bini, P., Gastaldi, M., Alfonsi, E., Pichiecchio, A., Rota, E., Rudà, R., Bruno, F., Villani, V., Galiè, E., Vogrig, A., Valente, M., Zoccarato, M., Poretto, V., Giometto, B., Cimminiello, C., Del Vecchio, M., & Marchioni, E. (2021). Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, . https://doi.org/10.1007/s10072-021-05561-z
Diamanti, Luca, et al. "Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience." Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology vol. (2021). doi: https://doi.org/10.1007/s10072-021-05561-z
Diamanti L, Picca A, Bini P, Gastaldi M, Alfonsi E, Pichiecchio A, Rota E, Rudà R, Bruno F, Villani V, Galiè E, Vogrig A, Valente M, Zoccarato M, Poretto V, Giometto B, Cimminiello C, Del Vecchio M, Marchioni E. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci. 2021 Aug 23; doi: 10.1007/s10072-021-05561-z. Epub 2021 Aug 23. PMID: 34424427.
Copy Download .nbib Format: NLM
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.

The oncologist

Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD.
PMID: 34355463
Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21.

BACKGROUND: Outcomes of patients with metastatic melanoma discontinuing BRAF-targeted therapy for cumulative toxicity after sustained response are unknown.MATERIALS AND METHODS: This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with BRAF mutated metastatic...

Cite
Di Guardo L, Randon G, Corti F, et al. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist. 2021;26(12):1079-1084doi: 10.1002/onco.13926.
Di Guardo, L., Randon, G., Corti, F., Vallacchi, V., Raimondi, A., Fucà, G., Bini, M., Maurichi, A., Patuzzo, R., Gallino, G., Mattavelli, I., Ruggeri, R., Angi, M., Cossa, M., Valeri, B., Cimminiello, C., Santinami, M., Rivoltini, L., de Braud, F., Rodolfo, M., & Vecchio, M. D. (2021). Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. The oncologist, 26(12), 1079-1084. https://doi.org/10.1002/onco.13926
Di Guardo, Lorenza, et al. "Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma." The oncologist vol. 26,12 (2021): 1079-1084. doi: https://doi.org/10.1002/onco.13926
Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. PMID: 34355463.
Copy Download .nbib Format: NLM
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.

The oncologist

Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD.
PMID: 34355463
Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21.

BACKGROUND: Outcomes of patients with metastatic melanoma discontinuing BRAF-targeted therapy for cumulative toxicity after sustained response are unknown.MATERIALS AND METHODS: This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with BRAF mutated metastatic...

Cite
Di Guardo L, Randon G, Corti F, et al. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist. 2021;26(12):1079-1084doi: 10.1002/onco.13926.
Di Guardo, L., Randon, G., Corti, F., Vallacchi, V., Raimondi, A., Fucà, G., Bini, M., Maurichi, A., Patuzzo, R., Gallino, G., Mattavelli, I., Ruggeri, R., Angi, M., Cossa, M., Valeri, B., Cimminiello, C., Santinami, M., Rivoltini, L., de Braud, F., Rodolfo, M., & Vecchio, M. D. (2021). Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. The oncologist, 26(12), 1079-1084. https://doi.org/10.1002/onco.13926
Di Guardo, Lorenza, et al. "Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma." The oncologist vol. 26,12 (2021): 1079-1084. doi: https://doi.org/10.1002/onco.13926
Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, Bini M, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma. Oncologist. 2021 Dec;26(12):1079-1084. doi: 10.1002/onco.13926. Epub 2021 Sep 21. PMID: 34355463; PMCID: PMC8649022.
Copy Download .nbib Format: NLM
Warfarin and atrial fibrillation: from ideal to real the warfarin affaire.

Thrombosis journal

Molteni M, Cimminiello C.
PMID: 24548437
Thromb J. 2014 Feb 18;12(1):5. doi: 10.1186/1477-9560-12-5.

Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral anticoagulation at least once in life. However, the rate of prescription of anticoagulation is low, compared to what it should...

Cite
Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J. 2014;12(1):5doi: 10.1186/1477-9560-12-5.
Molteni, M., & Cimminiello, C. (2014). Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thrombosis journal, 12(1), 5. https://doi.org/10.1186/1477-9560-12-5
Molteni, Mauro, and Cimminiello, Claudio. "Warfarin and atrial fibrillation: from ideal to real the warfarin affaire." Thrombosis journal vol. 12,1 (2014): 5. doi: https://doi.org/10.1186/1477-9560-12-5
Molteni M, Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J. 2014 Feb 18;12(1):5. doi: 10.1186/1477-9560-12-5. PMID: 24548437; PMCID: PMC3937065.
Copy Download .nbib Format: NLM
3β, 5α-Dihydroxy-6β-Methoxycholest-7-enes from the Marine Sponge Spongia agaricina.

Journal of natural products

Aiello A, Ciminiello P, Fattorusso E, Magno S.
PMID: 21401194
J Nat Prod. 1988 Sep;51(5):999-1002. doi: 10.1021/np50059a036.

No abstract available.

Cite
Aiello A, Ciminiello P, Fattorusso E, et al. 3β, 5α-Dihydroxy-6β-Methoxycholest-7-enes from the Marine Sponge Spongia agaricina. J Nat Prod. 1988;51(5):999-1002doi: 10.1021/np50059a036.
Aiello, A., Ciminiello, P., Fattorusso, E., & Magno, S. (1988). 3β, 5α-Dihydroxy-6β-Methoxycholest-7-enes from the Marine Sponge Spongia agaricina. Journal of natural products, 51(5), 999-1002. https://doi.org/10.1021/np50059a036
Aiello, A, et al. "3β, 5α-Dihydroxy-6β-Methoxycholest-7-enes from the Marine Sponge Spongia agaricina." Journal of natural products vol. 51,5 (1988): 999-1002. doi: https://doi.org/10.1021/np50059a036
Aiello A, Ciminiello P, Fattorusso E, Magno S. 3β, 5α-Dihydroxy-6β-Methoxycholest-7-enes from the Marine Sponge Spongia agaricina. J Nat Prod. 1988 Sep;51(5):999-1002. doi: 10.1021/np50059a036. PMID: 21401194.
Copy Download .nbib Format: NLM
Risk of venous thromboembolism in patients nursed at home or in long-term care residential facilities.

International journal of vascular medicine

Arpaia G, Ambrogi F, Penza M, Ianes AB, Serras A, Boracchi P, Cimminiello C.
PMID: 21748017
Int J Vasc Med. 2011;2011:305027. doi: 10.1155/2011/305027. Epub 2011 Jun 13.

Background. This study investigated the prevalence of and impact of risk factors for deep venous thrombosis (DVT) in patients with chronic diseases, bedridden or with greatly limited mobility, cared for at home or in long-term residential facilities. Methods. We...

Cite
Arpaia G, Ambrogi F, Penza M, et al. Risk of venous thromboembolism in patients nursed at home or in long-term care residential facilities. Int J Vasc Med. 2011;2011:305027doi: 10.1155/2011/305027.
Arpaia, G., Ambrogi, F., Penza, M., Ianes, A. B., Serras, A., Boracchi, P., & Cimminiello, C. (2011). Risk of venous thromboembolism in patients nursed at home or in long-term care residential facilities. International journal of vascular medicine, 2011305027. https://doi.org/10.1155/2011/305027
Arpaia, Guido, et al. "Risk of venous thromboembolism in patients nursed at home or in long-term care residential facilities." International journal of vascular medicine vol. 2011 (2011): 305027. doi: https://doi.org/10.1155/2011/305027
Arpaia G, Ambrogi F, Penza M, Ianes AB, Serras A, Boracchi P, Cimminiello C. Risk of venous thromboembolism in patients nursed at home or in long-term care residential facilities. Int J Vasc Med. 2011;2011:305027. doi: 10.1155/2011/305027. Epub 2011 Jun 13. PMID: 21748017; PMCID: PMC3124858.
Copy Download .nbib Format: NLM
A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.

Oncoimmunology

Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C.
PMID: 25941591
Oncoimmunology. 2014 Dec 21;3(11):e963406. doi: 10.4161/21624011.2014.963406. eCollection 2014 Nov.

Administration of NGR-TNF, a tumor vessel-targeting and tumor necrosis factor α TNFα) peptide conjugate, with immunotherapy has been shown to inhibit tumor growth in mice. Thus, we planned a Phase I pilot clinical trial to assess safety, immune and...

Cite
Parmiani G, Pilla L, Corti A, et al. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology. 2014;3(11):e963406doi: 10.4161/21624011.2014.963406.
Parmiani, G., Pilla, L., Corti, A., Doglioni, C., Cimminiello, C., Bellone, M., Parolini, D., Russo, V., Capocefalo, F., & Maccalli, C. (2014). A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology, 3(11), e963406. https://doi.org/10.4161/21624011.2014.963406
Parmiani, Giorgio, et al. "A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma." Oncoimmunology vol. 3,11 (2014): e963406. doi: https://doi.org/10.4161/21624011.2014.963406
Parmiani G, Pilla L, Corti A, Doglioni C, Cimminiello C, Bellone M, Parolini D, Russo V, Capocefalo F, Maccalli C. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. Oncoimmunology. 2014 Dec 21;3(11):e963406. doi: 10.4161/21624011.2014.963406. eCollection 2014 Nov. PMID: 25941591; PMCID: PMC4368149.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries